Quiet Harbor 52
Behind-the-scenes view accompanying the Texas ibogaine trial timeline
Texas public record · 2023—2028+

Trial Timeline

A chronological view of how Texas moved from legislation and a matching-grant appropriation toward a planned state-supported ibogaine research effort.

Follow the sequence

Dates below distinguish enacted measures, stated plans, and projected next steps. A projection is not a completed trial result.

Why chronology matters

Policy, funding, and research are separate stages.

Texas’ ibogaine initiative developed through legislation, appropriations, institutional coordination, and federal-facing protocol work. Those steps matter because a state-supported research pathway is not the same thing as ordinary treatment availability. For broader orientation, the Texas research overview sets out the distinction between public-policy activity and treatment access.

2023—2025

From bills to a research framework

The public record starts with the 88th Texas Legislature and continues through the work needed to turn statutory direction and appropriated funds into a study-ready program.

  1. Spring 2023

    SB 2308 and HB 3717 enter the legislative record.

    Both measures placed ibogaine-focused research in a Texas policy conversation shaped by veterans’ health, substance-use concerns, research oversight, and federal law. Legislative text and bill histories are maintained through the Texas Legislature Online bill record, where enacted language and procedural actions can be checked directly.

  2. June 2023

    SB 2308 becomes law.

    The enacted measure authorized a state-backed pathway for a clinical trial involving ibogaine and related compounds, subject to the conditions set out in law. The legislation did not change federal controlled-substance rules; the DEA’s drug scheduling explanation remains relevant to the legal setting in which federally regulated research must proceed.

  3. 2023 budget cycle

    A $50 million matching-grant structure is established.

    Texas appropriated up to $50 million for the effort through a matching-grant arrangement, meaning the state contribution was tied to non-state matching funds under the applicable terms. This was a research-funding mechanism, not an authorization for routine care and not evidence of a completed study outcome.

  4. 2024

    IMPACT consortium planning becomes visible.

    Public announcements identified the IMPACT consortium and participating academic settings including UTHealth Houston and UTMB, alongside partner sites. Building a multi-site study requires governance, study operations, regulatory planning, and defined responsibilities before recruitment can begin; the trial-process guide explains why those stages cannot be collapsed into a single announcement.

Research setting illustrating the protocol-development stage of Texas ibogaine trial planning

The work between headlines

A funded idea still has to become a protocol.

After legislative authorization and funding direction, the practical work shifts to protocol development, site preparation, review structures, data plans, and interactions with federal regulators. The U.S. Food and Drug Administration describes an Investigational New Drug application as the pathway through which sponsors seek authorization to administer an investigational drug in a clinical study.

Public references to FDA engagement should therefore be read as part of a regulated development sequence, not as a guarantee that enrollment has opened or that a product is approved. The broader history of clinical trials likewise underscores the difference between designing research and establishing a standard of care.

“The timeline is clearest when it separates what has been enacted or announced from what remains contingent on regulatory, institutional, and study steps.”
Reading the public record carefully

2025—2028+

Projected recruitment belongs at the end of the sequence.

Consortium materials and public discussion have pointed toward a multi-year development horizon, with projected recruitment dependent on completed protocol and regulatory work. Dates described as prospective should be understood as planning windows, not guarantees of a particular opening date, location, or eligibility route.

That distinction is especially important for people searching for immediate help. Information about ibogaine detox centers describes a different category from a state-supported research trial, just as questions about affordable ibogaine treatment do not establish that a public study offers treatment access, payment support, or enrollment.

Oversight remains part of the timeline.

Legislative appropriations, public statements, institutional updates, and future oversight or comment opportunities can all add to the record. The purpose of tracking them is accountability: it helps readers see when an action is documented, when a plan is still developing, and when a claim goes beyond available evidence.

For veterans and families, this can also clarify why material about ibogaine treatment for veterans or ibogaine for PTSD treatment should not be treated as proof of trial participation, safety, efficacy, or legal availability in Texas.

Keep the categories clear

Follow the evidence, not the implication.

Texas’ trial effort is a public research and policy development story. It does not settle medical questions, create personal eligibility, or replace individualized professional advice. The stakeholder FAQ context offers further plain-language distinctions for Texans, veterans, families, policymakers, and researchers.

Our research principles